January 27, 2022
We are pleased to announce that our strategic partner Adalvo has successfully launched Icatibant in 14 markets, with our Ambio group working in close collaboration in the development, synthesis, and manufacturing of this complex, injectable peptide product.
Icatibant is an equivalent and more affordable version of Firazyr (Takeda/Shire) that will now be made more accessible to patients world-wide and is a selective and competitive bradykinin B2 receptor antagonist which is used to treat acute attacks of hereditary angioedema (HAE), a serious orphan disease.
Icatibant is a landmark product and this commercial launch proves our abilities to bring complex high-value peptide drug products to the market.
Read the news from Adalvo here: https://www.adalvo.com/newsroom/adalvo-announces-successful-launch-of-icatibant